Skip to main content

Table 1 Characteristics of the patients

From: Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration

Patient Sex Age (years) Diagnosis Weight (kg) APACHE II The cause of AKI The value of Cre on admission to ICU (mg/dl) Duration of CHDF (days)
1 Male 75 Ruptured AAA 70.7 31 Hemorrhagic shock 1.32 66
2 Male 59 OHCA 88.9 42 PCAS 0.98 5
3 Male 46 Congenital heart disease 50.0 21 Major cardiac operation 0.69 45
4 Male 58 ML 58.3 41 Drug induced 2.04 38
Mean ± SE   59.5 ± 6.0 - 70.0 ± 8.5 33.8 ± 4.9 - 1.25 + 0.29 38.5 + 12.7
BUN (mmol/l) 24 h CL cre (ml/min) Q D (l/h) Q F (l/h) Predictive CL total (l/h) Calculated optimal dose of LVFX (mg)
42 3.4 1.0 2.0 4.0 200
43 0.9 1.0 2.0 4.0 200
40 - 1.0 2.0 - -
32 3.4 0.5 1.5 2.9 145
39.3 ± 5.0 2.6 ± 0.8 0.86 + 0.13 1.88 + 0.13 3.6 ± 0.4 182 + 18.3
  1. AAA abdominal aortic aneurysm, OHCA out-of-hospital cardiac arrest, ML malignant lymphoma, APACHE II Acute Physiology and Chronic Health Evaluation II score, AKI acute kidney injury, PCAS post-cardiac arrest syndrome, Cre creatinine, ICU intensive care unit, CHDF continuous hemodiafiltration, BUN blood urea nitrogen, CLcre creatinine clearance, CLtotal total clearance, QD dialysate flow, QF ultrafiltrate flow, LVFX levofloxacin, SE standard error.